[kvejdani]

There is only so much that can go into a short essay about the story and aspirations of a disruptive startup company. This story was not meant to be a scientific publication. We are working with FDA and expecting to receive approval within a year.

You can think of Darmiyan's product as a quantitative virtual microscope that, among other things, can help pharmaceutical companies come up with a disease-modifying treatment by testing the test drug on "cognitively healthy" volunteers who could potentially benefit from the drug, if it's really effective, before it's too late. Right now there is no other tool in the market to identify and monitor microscopic abnormality in cognitively healthy brains.